Gemfibrozil-induced peroxisome proliferation and hepatomegaly in male F344 rats
- 6 November 1995
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 97 (2) , 263-268
- https://doi.org/10.1016/0304-3835(95)03987-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liverCarcinogenesis: Integrative Cancer Research, 1993
- Rodent Carcinogens: Setting PrioritiesScience, 1992
- Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acidCarcinogenesis: Integrative Cancer Research, 1992
- Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication*1Fundamental and Applied Toxicology, 1992
- Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883Carcinogenesis: Integrative Cancer Research, 1991
- GemfibrozilDrugs, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Peroxisome proliferation due to di(2-ethylhexyl) phthalate (DEHP): species differences and possible mechanisms.Environmental Health Perspectives, 1986
- Evaluation of Selected Hypolipidemic Agents for the Induction of Peroxisomal Enzymes and Peroxisome Proliferation in the Rat LiverHuman Toxicology, 1983
- Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatmentAtherosclerosis, 1982